MRC1 and colorectal cancer: Previous studies have demonstrated that patients with MMR-deficient colorectal cancer are favorable candidates for immune checkpoint blockade, and screening of MMR-deficient tumors is performed for various kinds of malignancies over colorectal cancer [97,98].